NL300248I2 - Gesubstitueerde 3,5-difenyl-1,2,4-triazolen en de toepassing daarvan als farmaceutische metaal chelatoren. - Google Patents

Gesubstitueerde 3,5-difenyl-1,2,4-triazolen en de toepassing daarvan als farmaceutische metaal chelatoren.

Info

Publication number
NL300248I2
NL300248I2 NL300248C NL300248C NL300248I2 NL 300248 I2 NL300248 I2 NL 300248I2 NL 300248 C NL300248 C NL 300248C NL 300248 C NL300248 C NL 300248C NL 300248 I2 NL300248 I2 NL 300248I2
Authority
NL
Netherlands
Prior art keywords
triazoles
diphenyl
substituted
metal chelators
pharmaceutical metal
Prior art date
Application number
NL300248C
Other languages
English (en)
Dutch (nl)
Other versions
NL300248I1 (nl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4214048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL300248(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NL300248I1 publication Critical patent/NL300248I1/nl
Publication of NL300248I2 publication Critical patent/NL300248I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NL300248C 1996-06-25 2006-11-27 Gesubstitueerde 3,5-difenyl-1,2,4-triazolen en de toepassing daarvan als farmaceutische metaal chelatoren. NL300248I2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH159396 1996-06-25
PCT/EP1997/003315 WO1997049395A1 (en) 1996-06-25 1997-06-24 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators

Publications (2)

Publication Number Publication Date
NL300248I1 NL300248I1 (nl) 2007-02-01
NL300248I2 true NL300248I2 (nl) 2007-03-01

Family

ID=4214048

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300248C NL300248I2 (nl) 1996-06-25 2006-11-27 Gesubstitueerde 3,5-difenyl-1,2,4-triazolen en de toepassing daarvan als farmaceutische metaal chelatoren.

Country Status (36)

Country Link
US (3) US6465504B1 (en:Method)
EP (1) EP0914118B1 (en:Method)
JP (1) JP3541042B2 (en:Method)
KR (1) KR100616378B1 (en:Method)
CN (1) CN1146415C (en:Method)
AP (1) AP1127A (en:Method)
AR (1) AR007479A1 (en:Method)
AT (1) ATE226435T1 (en:Method)
AU (1) AU718037B2 (en:Method)
BG (1) BG64248B1 (en:Method)
BR (1) BR9709973A (en:Method)
CA (1) CA2255951C (en:Method)
CY (2) CY2429B1 (en:Method)
CZ (1) CZ291470B6 (en:Method)
DE (3) DE122007000020I1 (en:Method)
DK (1) DK0914118T3 (en:Method)
ES (1) ES2187785T3 (en:Method)
FR (1) FR06C0049I2 (en:Method)
GE (1) GEP20084355B (en:Method)
HU (1) HU226232B1 (en:Method)
IL (1) IL127212A0 (en:Method)
LT (1) LTC0914118I2 (en:Method)
LU (1) LU91291I2 (en:Method)
MY (1) MY129541A (en:Method)
NL (1) NL300248I2 (en:Method)
NO (3) NO317180B1 (en:Method)
NZ (1) NZ333308A (en:Method)
OA (1) OA10946A (en:Method)
PL (1) PL194758B1 (en:Method)
PT (1) PT914118E (en:Method)
RU (1) RU2208010C2 (en:Method)
SI (1) SI0914118T1 (en:Method)
SK (1) SK284319B6 (en:Method)
TR (1) TR199802693T2 (en:Method)
TW (1) TW533205B (en:Method)
WO (1) WO1997049395A1 (en:Method)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677487B2 (en) 2001-08-30 2004-01-13 Pharmacia Corporation α-haloenamine reagents
GB0126618D0 (en) 2001-11-06 2002-01-02 Novartis Ag Organic compounds
ES2192494B1 (es) * 2002-03-27 2005-02-16 Consejo Superior De Investigaciones Cientificas Derivados de 1,2,4-triazol con propiedades cannabinoides.
US8829198B2 (en) 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
GB0223978D0 (en) * 2002-10-15 2002-11-20 Novartis Ag Organic compound
AR044503A1 (es) * 2003-03-18 2005-09-14 Merck & Co Inc Triazoles sustituidos con biarilo como bloqueantes del canal de sodio
US20090227647A1 (en) 2008-03-05 2009-09-10 Thomas Lake Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes
US20050008699A1 (en) * 2003-07-11 2005-01-13 Fred Wehling Effervescent glucosamine composition
DE602004031667D1 (de) * 2003-11-10 2011-04-14 Merck & Co Inc Substituierte trialzole als blocker des natriumkanals
MXPA06006925A (es) * 2003-12-19 2006-08-23 Novartis Ag Combinacion de (a) n-{5-[4- (4-metil-piperazino -metil)-benzoilamido] 2-metilfenil}-4 -(3-piridil)-2 -pirimidina -amina y (b) por lo menos un inhibidor de hipusinacion y el uso de la misma.
GB0408078D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Organic compounds
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
CA2568134A1 (en) * 2004-05-24 2005-12-08 New York University Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
CA2594687C (en) * 2005-01-28 2013-10-29 Novartis Ag Use of pyrimidylaminobenzamides for the treatment of diseases that respond to modulation of tie-2 kinase activity
RU2007133712A (ru) * 2005-02-10 2009-03-20 Новартис АГ (CH) Способы улучшения распределения лекарственных средств
CA2608709A1 (en) * 2005-05-31 2006-12-07 Novartis Ag Treatment of liver diseases in which iron plays a role in pathogenesis
JP2009512652A (ja) * 2005-10-19 2009-03-26 ノバルティス アクチエンゲゼルシャフト 安息香酸誘導体含有分散錠
EP1945272B1 (en) * 2005-11-01 2013-09-11 Novartis AG Method of scintigraphy
PL1988083T3 (pl) * 2006-02-03 2014-08-29 Taisho Pharmaceutical Co Ltd Pochodna triazolowa
BRPI0711385A2 (pt) * 2006-05-09 2011-11-08 Novartis Ag combinação compreendendo um quelante de ferro e um agente anti-neoplástico e seu uso
KR20080112407A (ko) * 2006-05-23 2008-12-24 노파르티스 아게 유전적 혈색소증의 치료 방법
CL2007002026A1 (es) 2006-07-13 2008-06-06 Los Angeles Biomed Res Inst Composicion que comprende al menos un compuesto quelante de hierro y al menos un agente antifungico; y metodo para el tratamiento o prevencion de una condicion fungica.
JP2009545547A (ja) * 2006-08-04 2009-12-24 ノバルティス アクチエンゲゼルシャフト 鉄キレーターを使用した内分泌機能不全の処置
RU2339625C2 (ru) * 2006-11-02 2008-11-27 Российский химико-технологический университет (РХТУ им. Д.И. Менделеева) ЗАМЕЩЕННЫЕ N-[ω-АЗОЛ-1-ИЛ)АЛКИЛ]БЕНЗОЛСУЛЬФАМИДЫ В КАЧЕСТВЕ СРЕДСТВ С АНТИАГРЕГАЦИОННОЙ АКТИВНОСТЬЮ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
KR20090085081A (ko) * 2006-11-29 2009-08-06 노파르티스 아게 데페라시록스 (ｉｃｌ６７０ａ)의 다형체 형태
EP1927591A1 (en) * 2006-11-29 2008-06-04 Novartis AG Polymorphic Forms of Deferasirox (ICL670)
EP2108013A2 (en) * 2007-01-29 2009-10-14 Teva Gyógyszergyár Zártköruen Muködo Részvénytársaság Crystalline forms of deferasirox
AU2008250041A1 (en) * 2007-05-14 2008-11-20 Novartis Ag Use of iron chelator for the treatment of myocardial infarction
EP1994930A1 (en) * 2007-05-22 2008-11-26 Novartis AG Triazol compounds for treating biofilm formation
WO2009016359A1 (en) * 2007-07-27 2009-02-05 Pliva Hrvatska D.O.O. New forms of deferasirox
US20090082412A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched deferasirox
US20090142395A1 (en) 2007-11-19 2009-06-04 Uri Zadok Deferasirox pharmaceutical compositions
CZ301873B6 (cs) 2008-01-30 2010-07-14 Farmak, A. S. Zpusob prípravy kyseliny 4-[3,5-bis(2-hydroxyfenyl)-[1,2,4]triazol-1-yl]benzoové
WO2009106824A2 (en) * 2008-02-25 2009-09-03 Cipla Limited Pharmaceutical formulations
WO2009130604A2 (en) * 2008-04-21 2009-10-29 Actavis Group Ptc Ehf Solid state forms of deferasirox salts and process for the preparation thereof
US20110171138A1 (en) * 2008-06-02 2011-07-14 Actavis Group Ptc Ehf Substantially pure deferasirox and processes for the preparation thereof
US8623661B2 (en) 2008-09-22 2014-01-07 National University Corporation Asahikawa Medical College Iron chelating agent, method for producing same, method for determining amount of iron ions and method for trapping iron ions
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
WO2010092419A1 (en) 2009-02-12 2010-08-19 Assistance Publique - Hopitaux De Paris Combined treatment of multiple sclerosis
RU2011142173A (ru) 2009-03-19 2013-04-27 ЛОС-АНДЖЕЛЕС БАЙОМЕДИКАЛ РИСЕРЧ ИНСТИТЬЮТ ЭТ ХАБОР-ЮСиЭлЭй МЕДИКАЛ СЕНТР Вакцинные композиции и способы лечения мукоромикоза и других грибковых заболеваний
IT1398770B1 (it) * 2009-07-22 2013-03-18 Bellacchio Oligonucleotidi attivabili mediante l'appaiamento con sequenze di acidi nucleici e loro uso
WO2011021218A2 (en) * 2009-08-12 2011-02-24 Msn Laboratories Limited Process for the preparation of 4-[3,5-bis(2-hydroxyphenyl)-1h-1,2,4-triazol-1-yl]-benzoic acid and its amine salts
US8772503B2 (en) 2009-12-07 2014-07-08 Mapi Pharma Ltd. Processes for the preparation of deferasirox, and deferasirox polymorphs
EP2590630B1 (en) 2010-07-08 2015-04-29 ratiopharm GmbH Oral dosage form of deferasirox
EP2632907B1 (en) * 2010-08-25 2015-10-14 Davuluri, Ramamohan Rao Process for preparing 2-(2-hydroxyphenyl)-benz[1,3]oxazin-4-one and its use for preparing deferasirox
MX2013003522A (es) * 2010-10-01 2013-05-22 Cipla Ltd Composicion farmaceutica.
WO2012069946A1 (en) * 2010-11-24 2012-05-31 Alembic Pharmaceuticals Limited Process for the preparation of deferasirox
EP2664333B1 (en) 2011-01-14 2016-10-12 Disease Adsorption System Technologies Co., Ltd. Polymeric iron chelating agent
US20140276107A1 (en) 2011-10-14 2014-09-18 Photocure Asa Photodynamic diagnosis
WO2013053904A1 (en) 2011-10-14 2013-04-18 Photocure Asa Stent
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8642774B2 (en) * 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
AU2014224252B2 (en) * 2013-03-06 2016-09-22 Biocon Limited Process for the preparation of Deferasirox
MX361055B (es) * 2013-03-08 2018-11-26 Novartis Ag Formulaciones orales de deferasirox.
HK1215191A1 (zh) * 2013-05-10 2016-08-19 Cipla Limited 低剂量医药组合物
DE102013217390A1 (de) 2013-09-02 2015-03-05 Henkel Ag & Co. Kgaa Wasch- und Reinigungsmittel mit verbesserter Leistung
CN103454370B (zh) * 2013-09-11 2014-12-24 中美华世通生物医药科技（武汉）有限公司 一种利用hplc测定原料药中苯肼类化合物残留的方法
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
BR122024001145A2 (pt) 2014-03-14 2024-02-27 Novartis Ag Molécula de anticorpo isolada capaz de se ligar a lag-3, seu método de produção, composição farmacêutica, ácidos nucleicos, vetor de expressão, método para detecção de lag-3 em uma amostra biológica, e uso das referidas molécula de anticorpo e composição
EP2946771B1 (en) 2014-05-20 2019-03-20 Sanovel Ilac Sanayi ve Ticaret A.S. Water-dispersible tablet formulation comprising deferasirox
EP2987482A1 (en) 2014-08-22 2016-02-24 Santa Farma Ilaç Sanayi A.S. Soluble and dispersible pharamaceutical deferasirox formulation
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
AU2015333687B2 (en) 2014-10-14 2021-03-18 Dana-Farber Cancer Institute, Inc. Antibody molecules to PD-L1 and uses thereof
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
KR20160088965A (ko) 2015-01-16 2016-07-27 대원제약주식회사 데페라시록스를 함유하는 현탁제
KR20170129802A (ko) 2015-03-10 2017-11-27 아두로 바이오테크, 인코포레이티드 ＂인터페론 유전자의 자극인자＂-의존적 신호전달을 활성화하는 조성물 및 방법
CN104817538A (zh) * 2015-03-13 2015-08-05 东南大学 去铁斯诺-他克林金属离子鳌合剂及其药物用途
WO2016167729A1 (en) 2015-04-16 2016-10-20 Öğün Yusuf Toktamiş Dispersible tablets comprising deferasirox
EP3095443A1 (en) 2015-05-21 2016-11-23 Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. Pharmaceutical composition comprising deferasirox
WO2016203488A1 (en) * 2015-06-16 2016-12-22 Havaldar Freddy H Preparation of novel deferasirox analogues for antimalarial activity
SI3317301T1 (sl) 2015-07-29 2021-10-29 Novartis Ag Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
KR101695970B1 (ko) * 2015-07-31 2017-01-13 건일제약 주식회사 데페라시록스 함유 산제 및 그 제조방법
CN106554770B (zh) * 2015-09-29 2018-10-19 杭州杜易科技有限公司 一种三唑衍生物金属离子荧光探针及其制备方法和应用
CN108290878B (zh) 2015-10-23 2022-04-26 威佛（国际）股份公司 新的膜铁转运蛋白抑制剂
US20180371093A1 (en) 2015-12-17 2018-12-27 Novartis Ag Antibody molecules to pd-1 and uses thereof
WO2017158559A1 (en) 2016-03-17 2017-09-21 Lupin Limited Compositions of deferasirox
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018059922A1 (en) 2016-09-30 2018-04-05 Synthon B.V. Pharmaceutical composition comprising deferasirox
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CZ2017255A3 (cs) 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
WO2018208242A1 (en) 2017-05-10 2018-11-15 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Formulation of deferasirox tablet for oral suspension composition with better processability
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2019055490A1 (en) 2017-09-14 2019-03-21 The Board Of Trustees Of The Leland Stanford Junior University PACKAGING OF IRRADIED FABRIC FOR FAT GREETING RETENTION
EP3489692A1 (de) 2017-11-28 2019-05-29 Siemens Healthcare Diagnostics Products GmbH Prothrombinzeit-reagenz enthaltend einen eisenchelator
TR201722910A2 (tr) 2017-12-29 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Deferasi̇roks i̇çeren suda dağilabi̇len tablet formülasyonlari
KR20190110771A (ko) 2018-03-21 2019-10-01 주식회사 한국팜비오 데페라시록스를 함유하는 소형 분산성 정제
CN108727287B (zh) * 2018-05-10 2020-10-27 东南大学 1,2,4-三唑类化合物及其盐和应用
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
GR1009592B (el) * 2018-07-03 2019-09-11 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν χηλικο παραγοντα συμπλεκτικο του σιδηρου και μεθοδος για την παρασκευη αυτου
KR20200113116A (ko) 2019-03-22 2020-10-06 주식회사 한국팜비오 데페라시록스를 포함하는 필름코팅정제
TW202102478A (zh) 2019-04-01 2021-01-16 瑞士商威佛（國際）股份有限公司 新穎的鐵螯合物
CN114502590A (zh) 2019-09-18 2022-05-13 诺华股份有限公司 Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
IT202000000922A1 (it) 2020-01-20 2021-07-20 Cage Chemicals S R L Complessi di ferro e relativi sali come agenti di contrasto per MRI
US11155547B1 (en) * 2020-06-18 2021-10-26 Alterity Therapeutics Limited Compounds for and methods of treating diseases
EP4052698A1 (en) 2021-03-05 2022-09-07 Sanovel Ilac Sanayi Ve Ticaret A.S. Film coated tablet comprising deferasirox
CN114276305B (zh) * 2021-12-28 2023-11-17 中山大学 一种三取代苯基-1,2,4-三氮唑衍生物及其制备和治疗神经元损伤的应用
CN114591254B (zh) * 2022-03-31 2023-10-13 中山大学 一种3,5-二取代苯基-1,2,4-三氮唑衍生物及其制备方法和应用
CN114478410B (zh) * 2022-03-31 2022-11-29 中山大学 一种二取代苯基-1,2,4-三氮唑衍生物及其制备和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH388252A (de) 1963-01-24 1964-11-14 Geigy Ag J R Verfahren zum Schützen von Textilmaterial gegen Lichtschädigung
DE2628152C2 (de) 1976-06-23 1985-03-28 Bayer Ag, 5090 Leverkusen Fungizide und nematizide Mittel
US4528196A (en) * 1981-02-23 1985-07-09 The United States Of America As Represented By The Department Of Health And Human Services Chelating agents for the treatment of iron overload
SU1280851A1 (ru) * 1983-07-08 1996-05-27 Ростовский государственный университет 1-фенил-3-алкил-5-(o-оксифенил)-1,2,4-триазолы, обладающие транквилизирующим и антигипоксическим действием, и 1-фенил-3-н-бутил-5-(о-оксифенил)-1,2,4-триазол, обладающий транквилизирующим, антигипоксическим и анальгетическим действием
GB8429307D0 (en) 1984-11-20 1984-12-27 Shell Int Research Heterocyclic herbicides
IL84331A0 (en) * 1987-11-02 1988-04-29 Yissum Res Dev Co Pyridoxyl hydrazone derivatives and pharmaceutical compositions containing the same
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
DE4320801A1 (de) * 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel

Also Published As

Publication number Publication date
US20030069273A1 (en) 2003-04-10
US6723742B2 (en) 2004-04-20
DE69716602D1 (de) 2002-11-28
SK178598A3 (en) 1999-06-11
SK284319B6 (sk) 2005-01-03
GEP20084355B (en:Method) 2008-04-29
DE122007000020I2 (de) 2010-12-30
BG64248B1 (bg) 2004-07-30
OA10946A (en) 2003-02-27
HUP9903111A3 (en) 2000-06-28
CY2007005I1 (el) 2010-07-28
DK0914118T3 (da) 2003-02-24
CN1146415C (zh) 2004-04-21
LU91291I2 (fr) 2007-01-29
CN1223579A (zh) 1999-07-21
MY129541A (en) 2007-04-30
ATE226435T1 (de) 2002-11-15
HUP9903111A2 (hu) 2000-01-28
PT914118E (pt) 2003-02-28
EP0914118A1 (en) 1999-05-12
TR199802693T2 (xx) 1999-05-21
BR9709973A (pt) 1999-08-10
FR06C0049I2 (fr) 2007-04-27
CY2429B1 (en) 2004-11-12
CA2255951A1 (en) 1997-12-31
US6596750B2 (en) 2003-07-22
KR20050098029A (ko) 2005-10-10
AP1127A (en) 2002-12-06
DE69716602T2 (de) 2003-06-26
US20030203954A1 (en) 2003-10-30
CZ427298A3 (cs) 1999-03-17
RU2208010C2 (ru) 2003-07-10
LTPA2007001I1 (lt) 2018-06-25
LTC0914118I2 (lt) 2018-12-27
AU3262997A (en) 1998-01-14
NO986024D0 (no) 1998-12-21
SI0914118T1 (en) 2003-04-30
WO1997049395A1 (en) 1997-12-31
LU91291I9 (en:Method) 2018-12-27
JP3541042B2 (ja) 2004-07-07
FR06C0049I1 (en:Method) 2007-03-09
EP0914118B1 (en) 2002-10-23
NL300248I1 (nl) 2007-02-01
DE122007000020I1 (de) 2007-05-24
AP9801407A0 (en) 1998-12-31
NZ333308A (en) 2000-05-26
ES2187785T3 (es) 2003-06-16
NO986024L (no) 1998-12-21
AR007479A1 (es) 1999-10-27
PL194758B1 (pl) 2007-07-31
CZ291470B6 (cs) 2003-03-12
PL330119A1 (en) 1999-04-26
HK1020530A1 (en) 2000-05-12
NO2006017I1 (no) 2006-12-18
AU718037B2 (en) 2000-04-06
HU226232B1 (en) 2008-07-28
CA2255951C (en) 2006-10-10
NO2018014I2 (no) 2018-11-19
BG103003A (en) 1999-09-30
NO317180B1 (no) 2004-09-06
TW533205B (en) 2003-05-21
JP2000507601A (ja) 2000-06-20
CY2007005I2 (el) 2018-12-12
KR100616378B1 (ko) 2006-08-28
IL127212A0 (en) 1999-09-22
NO2018014I1 (no) 2018-04-17
US6465504B1 (en) 2002-10-15
NO2006017I2 (no) 2011-07-04

Similar Documents

Publication Publication Date Title
NL300248I2 (nl) Gesubstitueerde 3,5-difenyl-1,2,4-triazolen en de toepassing daarvan als farmaceutische metaal chelatoren.
PT915846E (pt) Fenilcetoenois 2-substituidos e 2,5-substituidos
NL350032I1 (nl) Pyrazool-4-yl-benzoylderivaten de toepassing ervan als herbiciden.
DE59608798D1 (de) Endoparasitizide mittel
DK1071433T3 (da) 2',2'-difluornucleosider til immunosuppressiv behandling og kombinationspræparater
DE59607589D1 (de) N-aryl-1,2,4-triazolin-5-one
PT811593E (pt) Agentes insecticidas e acaricidas 1,4-diaril-2-fluor-2-buteno
TR199501553A2 (tr) Sefem bilesimleri ve bunlarin farmasötik olarak kullanilmasi.
DE69636837D1 (de) 1,2,4-benzotriazinoxid-formulierungen
BR9708948A (pt) 1,3 - Benzodioxois substituídos
ITPN940023A0 (it) Mobile metallico per comunita'
ES1029825Y (es) Hucha perfeccionada.
ES1029171Y (es) Armario metalico perfeccionado.
IT1283187B1 (it) "elettrovalvola."
IT1274643B (it) Costruzione rapida "isodomus".
ITSV960001V0 (it) Dispositivo erogatore-distributore di sostanze in polvere o grnuli, in particolare saliera.
ES1030370Y (es) Rodamiento perfeccionado.
BR9711721A (pt) Paraherquamidas e marcfortinas de 24,25-epoxi e 25-metileno
ES1032570Y (es) Nuevo pijama perfeccionado.
ES1038556Y (es) "nuevo atril".
ES1034207Y (es) Cojunto de rodadura perfeccionado.
ES1036635Y (es) Buscapersonas perfeccionado.
ES1027222Y (es) Puerta metalica perfeccionada.
ES1028415Y (es) Puerta metalica perfeccionada.
ES1032699Y (es) Premarco perfeccionado.